CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the development of a sustained release formulation of bevacizumab for treating wet age-related macular degeneration. The aim is to enhance treatment effectiveness while improving safety and patient comfort through advanced drug delivery technology.
Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degenerationThis feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD).
AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects q…
CRITICAL PHARMACEUTICALS LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
